Lam, Carolyn S.P.

Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

Jackson, A. M., Jhund, P. S., Anand, I. S., Düngen, H.-D., Lam, C. S. P., Lefkowitz, M. P., Linssen, G., Lund, L. H., Maggioni, A. P., Pfeffer, M. A., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 156

Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes

Filippatos, G., Bakris, G. L., Pitt, B., Agarwal, R., Rossing, P., Ruilope, L. M., Butler, J., Lam, C. S. P., Kolkhof, P., Roberts, L., et al. (2021) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesChronic Kidney Disease and Diabetes

Cited by 153

Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models

Withaar, C., Lam, C. S. P., Schiattarella, G. G., de Boer, R. A., & Meems, L. M. G. (2021) · European Heart Journal

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 150

N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes

Ezekowitz, J. A., O’Connor, C. M., Troughton, R. W., Alemayehu, W. G., Westerhout, C. M., Voors, A. A., Butler, J., Lam, C. S. P., Ponikowski, P., Emdin, M., et al. (2020) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

Cited by 146

Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project

Arnold, S. V., Inzucchi, S. E., Tang, F., McGuire, D. K., Mehta, S. N., Maddox, T. M., Goyal, A., Sperling, L. S., Einhorn, D., Wong, N. D., et al. (2017) · European Journal of Preventive Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 144

Patient selection in heart failure with preserved ejection fraction clinical trials

Kelly, J. P., Mentz, R. J., Mebazaa, A., Voors, A. A., Butler, J., Roessig, L., Fiuzat, M., Zannad, F., Pitt, B., O’Connor, C. M., et al. (2015) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 139

Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial

Lam, C. S. P., Ramasundarahettige, C., Branch, K. R. H., Sattar, N., Rosenstock, J., Pratley, R., Del Prato, S., Lopes, R. D., Niemoeller, E., Khurmi, N. S., et al. (2022) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 132

Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice

McDonagh, T., Damy, T., Doehner, W., Lam, C. S. P., Sindone, A., van der Meer, P., Cohen-Solal, A., Kindermann, I., Manito, N., Pfister, O., et al. (2018) · European Journal of Heart Failure

Iron Metabolism and DisordersErythropoietin and Anemia Treatment

Cited by 121

Prevalence and clinical significance of diabetes in asian versus white patients with heart failure

Bank, I. E. M., Gijsberts, C. M., Teng, T.-H. K., Benson, L., Sim, D., Yeo, P. S. D., Ong, H. Y., Jaufeerally, F., Leong, G. K. T., Ling, L. H., et al. (2017) · JACC Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 87

Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction

Kosiborod, M. N., Bhatt, A. S., Claggett, B. L., Vaduganathan, M., Kulac, I. J., Lam, C. S. P., Hernandez, A. F., Martinez, F. A., Inzucchi, S. E., Shah, S. J., et al. (2023) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 86

Microvascular endothelial dysfunction in heart failure with preserved ejection fraction

Lam, C. S. P., & Lund, L. H. (2016) · Heart

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 81

The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF

Withaar, C., Meems, L. M. G., Nollet, E. E., Schouten, E. M., Schroeder, M. A., Knudsen, L. B., Niss, K., Madsen, C. T., Hoegl, A., Mazzoni, G., et al. (2023) · JACC: Basic to Translational Science

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 74

Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction

Lam, C. S. (2015) · Diabetes and Vascular Disease Research

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 69

Central and peripheral determinants of exercise capacity in heart failure patients with preserved ejection fraction

Wolsk, E., Kaye, D., Komtebedde, J., Shah, S. J., Borlaug, B. A., Burkhoff, D., Kitzman, D. W., Lam, C. S. P., van Veldhuisen, D. J., Ponikowski, P., et al. (2019) · JACC Heart Failure

Cardiovascular and exercise physiologyHeart Failure Treatment and Management

Cited by 43

Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF

Yang, M., Henderson, A. D., Talebi, A., Atherton, J. J., Chiang, C.-E., Chopra, V., Comin-Colet, J., Kosiborod, M. N., Kerr Saraiva, J. F., Claggett, B. L., et al. (2025) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementHormonal Regulation and Hypertension

Cited by 41

Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity

Mentias, A., Desai, M. Y., Aminian, A., Patel, K. V., Keshvani, N., Verma, S., Cho, L., Jacob, M., Alvarez, P., Lincoff, A. M., et al. (2024) · Circulation: Heart Failure

Bariatric Surgery and OutcomesHeart Failure Treatment and Management

Cited by 40

Optimal screening for predicting and preventing the risk of heart failure among adults with diabetes without atherosclerotic cardiovascular disease: a pooled cohort analysis

Patel, K. V., Segar, M. W., Klonoff, D. C., Khan, M. S., Usman, M. S., Lam, C. S. P., Verma, S., DeFilippis, A. P., Nasir, K., Bakker, S. J. L., et al. (2024) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 38

Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence

Khunti, K., Aroda, V. R., Bhatt, D. L., Bozkurt, B., Buse, J. B., Heerspink, H. L., Inzucchi, S. E., Lam, C. S. P., Marx, N., McMurray, J. J. V., et al. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 37

Digital tools in heart failure: addressing unmet needs

Myhre, P. L., Tromp, J., Ouwerkerk, W., Ting, D. S. W., Docherty, K. F., Gibson, C. M., & Lam, C. S. P. (2024) · The Lancet Digital Health

Heart Failure Treatment and ManagementMobile Health and mHealth Applications

Cited by 31

Moving Beyond the Model

Jain, S. S., Mortazavi, B. J., Chan You, S., Yao, X., Lam, C. S. P., Elias, P., Poterucha, T. J., Avram, R., Tison, G. H., Pirruccello, J., et al. (2025) · JACC

Clinical practice guidelines implementationHealth and Medical Research Impacts

Cited by 13